High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.
The deal adds telehealth operations in Australia, Canada and Japan.
Hims & Hers Health (NYSE:HIMS) has completed the acquisition of Eucalyptus. The deal extends the company’s presence into Japan, Germany, Canada, and Australia. Eucalyptus brings established consumer brands and clinical infrastructure in weight management and whole body care. Hims & Hers Health runs a direct to consumer telehealth and wellness platform, connecting patients with licensed clinicians and tailored treatment plans. By bringing Eucalyptus under its umbrella, the company now has a...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.